Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Breast

Volumn 28, Issue , 2016, Pages 191-198

  Curigliano, G ^a   Gomez Pardo P ^b   Meric Bernstam, F ^c   Conte, P ^d,e   Lolkema, M P ^f,g   Beck, J T ^h   Bardia, A ⁱ   Martinez Garcia M ^j   Penault Llorca, F ^k   Dhuria, S ^l   Tang, Z ^l   Solovieff, N ^m   Miller, M ^l   Di Tomaso, E ^m   Hurvitz, S A ⁿ  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g ERASMUS MC CANCER INSTITUTE   (Netherlands)

^h Highlands Oncology Group   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j HOSPITAL DEL MAR   (Spain)

^k CENTRE JEAN PERRIN   (France)

^l NOVARTIS PHARMA AG   (Switzerland)

^m NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

ⁿ Santa Monica UCLA Medical Center   (United States)

more..

Author keywords

Breast cancer; CDK4 6; Letrozole; Ribociclib

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LETROZOLE; RETINOBLASTOMA PROTEIN; RIBOCICLIB; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CCND2 PROTEIN, HUMAN; CCND3 PROTEIN, HUMAN; CCNE1 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN D2; CYCLIN D3; CYCLIN E; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; NITRILE; ONCOPROTEIN; PROGESTERONE RECEPTOR; PURINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CCND2 GENE; CCND3 GENE; CCNE1 GENE; CDK4 GENE; CDK6 GENE; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GENE; GENE EXPRESSION; GENETIC SCREENING; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOMAGNESEMIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BLOOD; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NEOADJUVANT THERAPY; PHASE 2 CLINICAL TRIAL; SIGNAL TRANSDUCTION;

AGED; AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLIN D2; CYCLIN D3; CYCLIN E; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; ONCOGENE PROTEINS; PURINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84975215690     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2016.06.008     Document Type: Article

References (36)

1. Thangavel C., Dean J.L., Ertel A., Knudsen K.E., Aldaz C.M., Witkiewicz A.K., et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011, 18:333-345.
2. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., et al. Final overall survival: fulvestrant 500mg vs 250mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014, 106. djt337.
3. Schmitz S., Duhoux F., Machiels J. Window of opportunity studies: do they fulfil our expectations?. Cancer Treat Rev 2016, 43:50-57.
4. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
5. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., et al. A phase II placebo-controlled trial of neoadjuvant anstrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822.
6. Guix M., Granja Nde M., Meszoely I., Adkins T.B., Wieman B.M., Frierson K.E., et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008, 26:897-906.
7. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996, 16:6917-6925.
8. Hosford S.R., Miller T.W. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med 2014, 7:203-215.
9. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602:73-87.
10. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
11. Knudsen E.S., Wang J.Y. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010, 16:1094-1099.
12. Rader J., Russell M.R., Hart L.S., Nakazawa M.S., Belcastro L.T., Martinez D., et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013, 19:6173-6182.
13. Kim S., Loo A., Chopra R., Caponigro G., Huang A., Vora S., et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther 2013, 12(11 Suppl). Abstract PR02.
14. O'Brien N.A., Di Tomaso E., Ayala R., Tong L., Issakhanian S., Linnartz R., et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res 2014, 74(19 Suppl). Abstract 4756.
15. Munster P.N., Hamilton E.P., Garcia-Estevez L., De Boer R.H., Mayer I.A., Campone M., et al. Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer. J Clin Oncol 2014, 32(26 Suppl). Abstract 143.
16. Juric D., Hamilton E., Garcia-Estevez L., De Boer R.H., Mayer I., Campone M., et al. Phase Ib/II study of LEE011 and alpelisib (BYL719) and letrozole in ER+, HER2- breast cancer: safety, preliminary efficacy and molecular analysis. Cancer Res 2015, 75(9 Suppl). Abstract P5-19-24.
17. Infante J.R., Shapiro G.I., Witteveen P.O., Gerecitano J.F., Ribrag V., Chugh R., et al. Phase I multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Mol Cancer Ther 2013, 12(11 Suppl). Abstract A276.
18. Mamo A., Cavallone L., Tuzmen S., Chabot C., Ferrario C., Hassan S., et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012, 31:2090-2100.
19. Infante J.R., Shapiro G., Witteveen P., Gerecitano J.F., Ribrag V., Chugh R., et al. A phase I study of the single-agent CDk4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 2014, 32(15 Suppl). Abstract 2528.
20. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637.
21. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220.
22. Ma C.X., Gao F., Northfelt D., Goetz M., Forero A., Naughton M., et al. A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC). Cancer Res 2016, 76(4 Suppl). Abstract S6-S05.
23. Bardia A., Chavez-MacGregor M., Modi S., Campone M., Ma B., Kittaneh M., et al. Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2- advanced/metastatic breast cancer: results from a Phase Ib clinical trial. Eur J Cancer 2014, 50(6 Suppl). Abstract 500.
24. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015, 16:25-35.
25. Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 2 randomised controlled trial. Lancet Oncol 2016, 17:425-439.
26. Rubin S.M. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci 2013, 38:12-19.
27. Dick F.A., Rubin S.M. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013, 14:297-306.
28. Choudhury K.R., Yagle K.J., Swanson P.E., Krohn K.A., Rajendran J.G. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem 2010, 58:95-107.
29. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6. 224ra24.
30. Zhang L., Riethdorf S., Wu G., Wang T., Yang K., Peng G., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012, 18:5701-5710.
31. Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012, 18:3462-3469.
32. De Mattos-Arruda L., Weigelt B., Cortes J., Won H.H., Ng C.K.Y., Nuciforo P., et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014, 25:1729-1735.
33. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695.
34. Bratman S.V., Newman A.M., Alizadeh A.A., Diehn M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn 2015, 15:715-719.
35. Novartis press release. Accessed May 2016. https://www.novartis.com/news/media-releases/monaleesa-2-trial-novartis-lee011-ribociclib-stopped-due-positive-efficacy.
36. COSMIC Database v66. Accessed May 2016. http://cancer.sanger.ac.uk/cosmic.